My account

Injectables Orals Peptides Human Growth Hormone SARMs

A

Anastrozole

B

Bacteriostatic water Boldenone undecylenate

C

Clenbuterol Clomiphene citrate Cabergoline

D

Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)

E

Erythropoietin Exemestane

F

Fluoxymesterone

H

Human chorionic gonadotropin Human growth hormone

L

Liothyronine sodium

M

Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2

N

Nandrolone decanoate Nandrolone phenylpropionate

O

Oxandrolone Oxymetholone

S

Sildenafil citrate Stanozolol

T

Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol

Y

Yohimbine

Show 164 results

Substances

Disagree

Home

Substances

Tirzepatide

Tirzepatide - Page 2

A-Z

1 2

Substance Overview and History

Tirzepatide (marked as "Mounjaro") is a novel dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for Type 2 Diabetes(T2D) management. Developed by company Eli Lilly it helps control blood sugar and supports significant weight loss by targeting two pathways. Showed superior results compared to standard GLP-1 therapies in reducing HbA1c and body weight, with a safety profile similar to existing treatments, making it a new option for managing T2D effectively.

References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ

What is Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for Type 2 Diabetes (T2D) treatment, marketed as Mounjaro® by Eli Lilly.

References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

How does Tirzepatide work?

It targets both GIP and GLP1 receptors in result lower blood sugar and promote weight loss.

References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.

When was Tirzepatide approved by the FDA?

Tirzepatide was approved by the FDA in May 2022.

References:

Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.